Based on these lines of evidence, RET over-expression in BC might be due to transcriptional mechanisms involving estrogen receptors and chromatin conformation, so that targeting the RET pathway may lead to the development of new therapies in ER+ BC. The gene discussed is RET; the disease is breast cancer.